Krystal Biotech Inc (NASDAQ:KRYS) has seen over $250 million in net VYJUVEK revenue since August 2023. The company reported positive revenue growth, strong profitability, and progress in Europe. However, litigation expenses and seasonal disruptions are challenges.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing